Table 2.
Demographic, genetic, and biochemical data in the individual subcohorts
| Total cohort (n = 716) | Cohort 1a (n = 138) | Cohort 1b (n = 72) | Cohort 2 (n = 81) | Cohort 3 (n = 121) | Cohort 4 (n = 39) | Cohort 5 (n = 37) | Cohort 6 (n = 48) | Cohort 7 (n = 58) | Cohort 8 (n = 24) | Cohort 9 (n = 44) | Cohort 10 (n = 54) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Location | Gothenburg, Sweden | Gothenburg, Sweden | Perugia, Italy | Stockholm, Sweden | Malmö, Sweden | Malmö, Sweden | Mölndal, Sweden | Kuopio, Finland | Munich, Germany | Stockholm, Sweden | Mölndal, Sweden | |
| Type of clinic | Affective disorders clinic | Affective disorders clinic | Memory clinic | Memory clinic | Memory clinic | Memory clinic | Memory clinic | Memory clinic | Memory clinic | Memory clinic | Memory clinic | |
| Diagnosis | Bipolar disorder | Controls | Controls | Controls | Controls | Controls | Controls | Controls | Controls | Controls | Controls | |
| Age (years), mean (range) | 53.3 (17–99) | 39.4 (20–73) | 37.9 (21–74) | 53.0 (21–88) | 68.0 (40–92) | 72.4 (60–87) | 62.9 (42–99) | 66.6 (52–80) | 65.6 (45–81) | 63.0 (49–84) | 60.9 (23–88) | 22.0 (17–34) |
| Male, n (%) | 305 (42.6) | 55 (39.9) | 27 (37.5) | 22 (27.2) | 36 (29.8) | 15 (38.5) | 16 (43.2) | 22 (45.8) | 30 (51.7) | 15 (62.5) | 19 (43.2) | 48 (88.9) |
| Female, n (%) | 411 (57.4) | 83 (60.1) | 45 (62.5) | 59 (72.8) | 85 (70.2) | 24 (61.5) | 21 (56.8) | 26 (54.2) | 28 (48.3) | 9 (37.5) | 25 (56.8) | 6 (11.1) |
| APOE ε4–/–, n (%) | 506 (70.7) | 93 (67.4) | 49 (68.1) | 65 (80.2) | 88 (72.7) | 29 (74.4) | 25 (67.6) | 32 (66.7) | 40 (69.0) | 19 (79.2) | 31 (70.5) | 35 (64.8) |
| APOE ε4+/–, n (%) | 190 (26.5) | 41 (29.7) | 20 (27.8) | 14 (17.3) | 32 (26.4) | 10 (25.6) | 10 (27.0) | 15 (31.3) | 16 (27.6) | 5 (20.8) | 11 (25.0) | 16 (29.6) |
| APOE ε4+/+, n (%) | 20 (2.8) | 4 (2.9) | 3 (4.2) | 2 (2.5) | 1 (0.8) | 0 (0.0) | 2 (5.4) | 1 (2.1) | 2 (3.4) | 0 (0.0) | 2 (4.5) | 3 (5.6) |
| CSF Aβ42 assay and concentrations measured (ng/L), mean (SD) | xMAP Luminex AlzBio3 | xMAP Luminex AlzBio3 | INNOTEST β-amyloid[1–42] | INNOTEST β-amyloid[1–42] | INNOTEST β-amyloid[1–42] | xMAP Luminex AlzBio3 | INNOTEST β-amyloid[1–42] | INNOTEST β-amyloid[1–42] | INNOTEST β-amyloid[1–42] | INNOTEST β-amyloid[1–42] | INNOTEST β-amyloid[1–42] | |
| All genotypes | 252.1 (71.0) | 257.7 (57.7) | 255.1 (54.2) | 260.2 (91.5) | 250.8 (75.8) | 260.3 (67.6) | 245.4 (58.7) | 250.3 (39.8) | 242.2 (71.9) | 247.6 (72.3) | 259.0 (92.4) | 232.1 (84.6) |
| APOE ε4–/– | 261.2 (70.9) | 264.6 (57.2) | 259.8 (51.7) | 262.5 (93.9) | 264.0 (68.2) | 260.8 (66.0) | 257.5 (66.2) | 258.3 (36.8) | 258.5 (75.0) | 260.9 (72.9) | 276.6 (89.1) | 240.6 (93.0) |
| APOE ε4+/– | 234.8 (65.4) | 250.5 (51.4) | 245.3 (63.1) | 266.4 (76.0) | 219.7 (82.5) | 258.9 (75.7) | 220.3 (29.0) | 241.7 (31.4) | 205.4 (52.2) | 197.0 (46.3) | 230.0 (90.4) | 216.0 (66.6) |
| APOE ε4+/+ | 185.5 (59.0) | 172.0 (67.9) | 243.3 (21.1) | 139.3 (24.6) | 87.5 (N/A) | N/A | 219.2 (13.4) | 125.7 (N/A) | 209.7 (10.0) | N/A | 143.9 (31.5) | 218.0 (75.1) |
APOE apolipoprotein E, Aβ42 beta-amyloid1–42, CSF cerebrospinal fluid, SD standard deviation, N/A not available